India: Life Sciences, Biotechnology & Nanotechnology

India's life sciences and healthcare sector saw significant regulatory shifts in April 2026, including proposed decriminalization of minor violations, new medical device testing fees, and streamlined foreign training requirements for healthcare professionals. Courts also delivered key rulings on pharmaceutical trademark disputes, reinforcing stricter standards for drug name similarity.

India's healthcare and pharmaceutical sectors are undergoing significant regulatory transformation through new frameworks for AI adoption, enhanced surveillance of drug supply chains, and streamlined approval processes.

On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon...

In the past couple of months, India's healthcare and pharmaceutical sectors have seen a continued push towards regulatory strengthening, quality standardisation, and innovation-driven growth.

India is known as the "pharmacy of the world" due to the low cost and high quality of its medicines, cementing its important position in the global pharmaceutical industry.

In contemporary India, speed and convenience have become defining features of consumer behaviour, particularly with the rise of e-commerce and quick-commerce platforms.

The Ministry of Consumer Affairs, Food and Public Distribution has notified the Legal Metrology (General) Third Amendment Rules, 2025...

In the fiercely competitive world of trademarks, a single word or phrase can become a powerful symbol distinguishing a business, securing its reputation, and fostering loyalty among consumers

The Central Drugs Standard Control Organisation ("CDSCO") has revised the process of issuing No Objection Certificates (NOC) for the export of unapproved/approved new drugs from India as of 7th May 2025...